Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Circulation ; 149(5): 391-401, 2024 01 30.
Article in English | MEDLINE | ID: mdl-37937463

ABSTRACT

BACKGROUND: High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide. Although atherosclerosis is commonly treated with low-density lipoprotein-targeting therapies, these do not reduce Lp(a) or risk of calcific aortic valve disease, which has no available drug therapies. Targeting Lp(a) production and catabolism may provide therapeutic benefit, but little is known about Lp(a) cellular uptake. METHODS: Here, unbiased ligand-receptor capture mass spectrometry was used to identify MFSD5 (major facilitator superfamily domain containing 5) as a novel receptor/cofactor involved in Lp(a) uptake. RESULTS: Reducing MFSD5 expression by a computationally identified small molecule or small interfering RNA suppressed Lp(a) uptake and calcification in primary human valvular endothelial and interstitial cells. MFSD5 variants were associated with aortic stenosis (P=0.027 after multiple hypothesis testing) with evidence suggestive of an interaction with plasma Lp(a) levels. CONCLUSIONS: MFSD5 knockdown suppressing human valvular cell Lp(a) uptake and calcification, along with meta-analysis of MFSD5 variants associating with aortic stenosis, supports further preclinical assessment of MFSD5 in cardiovascular diseases, the leading cause of death worldwide.


Subject(s)
Aortic Valve Disease , Aortic Valve Stenosis , Atherosclerosis , Calcinosis , Heart Valve Diseases , Humans , Aortic Valve/metabolism , Aortic Valve Disease/metabolism , Aortic Valve Stenosis/drug therapy , Aortic Valve Stenosis/genetics , Atherosclerosis/metabolism , Heart Valve Diseases/drug therapy , Heart Valve Diseases/genetics , Heart Valve Diseases/complications , Lipoprotein(a) , Risk Factors
2.
Circulation ; 148(19): 1459-1478, 2023 11 07.
Article in English | MEDLINE | ID: mdl-37850387

ABSTRACT

BACKGROUND: Interferon-γ (IFNγ) signaling plays a complex role in atherogenesis. IFNγ stimulation of macrophages permits in vitro exploration of proinflammatory mechanisms and the development of novel immune therapies. We hypothesized that the study of macrophage subpopulations could lead to anti-inflammatory interventions. METHODS: Primary human macrophages activated by IFNγ (M(IFNγ)) underwent analyses by single-cell RNA sequencing, time-course cell-cluster proteomics, metabolite consumption, immunoassays, and functional tests (phagocytic, efferocytotic, and chemotactic). RNA-sequencing data were analyzed in LINCS (Library of Integrated Network-Based Cellular Signatures) to identify compounds targeting M(IFNγ) subpopulations. The effect of compound BI-2536 was tested in human macrophages in vitro and in a murine model of atherosclerosis. RESULTS: Single-cell RNA sequencing identified 2 major clusters in M(IFNγ): inflammatory (M(IFNγ)i) and phagocytic (M(IFNγ)p). M(IFNγ)i had elevated expression of inflammatory chemokines and higher amino acid consumption compared with M(IFNγ)p. M(IFNγ)p were more phagocytotic and chemotactic with higher Krebs cycle activity and less glycolysis than M(IFNγ)i. Human carotid atherosclerotic plaques contained 2 such macrophage clusters. Bioinformatic LINCS analysis using our RNA-sequencing data identified BI-2536 as a potential compound to decrease the M(IFNγ)i subpopulation. BI-2536 in vitro decreased inflammatory chemokine expression and secretion in M(IFNγ) by shrinking the M(IFNγ)i subpopulation while expanding the M(IFNγ)p subpopulation. BI-2536 in vivo shifted the phenotype of macrophages, modulated inflammation, and decreased atherosclerosis and calcification. CONCLUSIONS: We characterized 2 clusters of macrophages in atherosclerosis and combined our cellular data with a cell-signature drug library to identify a novel compound that targets a subset of macrophages in atherosclerosis. Our approach is a precision medicine strategy to identify new drugs that target atherosclerosis and other inflammatory diseases.


Subject(s)
Atherosclerosis , Plaque, Atherosclerotic , Humans , Animals , Mice , Gene Regulatory Networks , Macrophages/metabolism , Atherosclerosis/genetics , Plaque, Atherosclerotic/metabolism , RNA/metabolism , Biology
3.
Front Cardiovasc Med ; 9: 842641, 2022.
Article in English | MEDLINE | ID: mdl-35402570

ABSTRACT

Conventional drug screening methods search for a limited number of small molecules that directly interact with the target protein. This process can be slow, cumbersome and has driven the need for developing new drug screening approaches to counter rapidly emerging diseases such as COVID-19. We propose a pipeline for drug repurposing combining in silico drug candidate identification followed by in vitro characterization of these candidates. We first identified a gene target of interest, the entry receptor for the SARS-CoV-2 virus, angiotensin converting enzyme 2 (ACE2). Next, we employed a gene expression profile database, L1000-based Connectivity Map to query gene expression patterns in lung epithelial cells, which act as the primary site of SARS-CoV-2 infection. Using gene expression profiles from 5 different lung epithelial cell lines, we computationally identified 17 small molecules that were predicted to decrease ACE2 expression. We further performed a streamlined validation in the normal human epithelial cell line BEAS-2B to demonstrate that these compounds can indeed decrease ACE2 surface expression and to profile cell health and viability upon drug treatment. This proposed pipeline combining in silico drug compound identification and in vitro expression and viability characterization in relevant cell types can aid in the repurposing of FDA-approved drugs to combat rapidly emerging diseases.

4.
Front Cardiovasc Med ; 8: 826529, 2021.
Article in English | MEDLINE | ID: mdl-35127876

ABSTRACT

Vascular calcification is a cardiovascular disorder with no therapeutic options. We recently reported that o-octanoyltransferase (CROT) suppression can inhibit vascular calcification in vivo and in vitro through amelioration of mitochondrial function and fatty acid metabolism. Inhibiting calcification with a small molecule compound targeting CROT-associated mechanisms will be a promising non-invasive treatment of vascular calcification. Here we used a computational approach to search for existing drugs that can inhibit vascular calcification through the CROT pathway. For screening of the compounds that reduce CROT expression, we utilized the Connectivity Map encompassing the L1000 computational platform that contains transcription profiles of various cell lines and perturbagens including small molecules. Small molecules (n = 13) were identified and tested in human primary smooth muscle cells cultured in osteogenic media to induce calcification. Niclosamide, an FDA-improved anthelmintic drug, markedly inhibited calcification along with reduced alkaline phosphatase activity and CROT mRNA expression. To validate this compound in vivo, LDL receptor (Ldlr)-deficient mice fed a high fat diet were given oral doses of niclosamide (0 or 750 ppm admixed with diet) for 10 weeks. Niclosamide treatment decreased aortic and carotid artery calcification as determined by optical near infrared molecular imaging (OsteoSense680) and histological analysis. In addition, niclosamide improved features of fatty liver, including decreased cholesterol levels along with decreased Crot expression, while plasma total cholesterol levels did not change. Proteomic analysis of aortic samples demonstrated that niclosamide affected wingless/integrated (Wnt) signaling pathway and decreased runt-related transcription factor 2 (Runx2) expression, an essential factor for calcification. Our target discovery strategy using a genetic perturbation database with existing drugs identified niclosamide, that in turn inhibited calcification in vivo and in vitro, indicating its potential for the treatment of vascular calcification.

5.
Article in English | MEDLINE | ID: mdl-20879298

ABSTRACT

Visceral fat area (VFA) has close relationship with hypertension, diabetes and cardiovascular disease, and therefore serve as a reliable indicator of these diseases. Abdominal computed tomography (CT) enables precise quantification of the VFA and has been considered as the gold standard for VFA assessment. In this paper, we develope a novel method to quickly and accurately measure the VFA with ultrasonography (US). We evaluated the novel method on five volunteers and the diagnosis procedures lasted less than 30 seconds averagely. The simulation results by our method were compared with VFA estimated by abdominal CT. The correlation coefficient between them was 0.913 for men and 0.858 for women. And the mean deviation of between VFA by CT and by our method was 19.8 cm2 for men and 13.3 cm2 for women.


Subject(s)
Image Interpretation, Computer-Assisted/methods , Intra-Abdominal Fat/diagnostic imaging , Transducers , Ultrasonography/instrumentation , Equipment Design , Equipment Failure Analysis , Humans , Image Enhancement/methods , Reproducibility of Results , Sensitivity and Specificity
6.
J Biosci Bioeng ; 109(6): 638-44, 2010 Jun.
Article in English | MEDLINE | ID: mdl-20471607

ABSTRACT

A new and simple method based on the mechanism of detoxification of metallothionein was developed by using a water-soluble porphyrin and Zn(II)-bound metallothionein for evaluating heavy metal toxicity. Labile Zn(II) ions were released when toxic metal ions such as Cu(II), Pb(II), Bi(III), Cd(II), Hg(II), Co(II), Ag(I), and Ni(II) bound to Zn(II)-bound metallothionein. The water-soluble porphyrin, 5,10,15,20-tetraphenyl-21H,23H-porphinetetrasulfonic acid, a chromogenic reagent that is highly sensitive to Zn(II), formed a complex with the labile Zn(II) ions. The absorption change at 423 nm resulting from the formation of the Zn(II)-porphyrin complex was used to evaluate the toxicity of sample solutions containing different metal ions. The absorption change was well correlated with the toxicity, which was evaluated by a bioluminescence inhibition assay using the bioluminescent bacteria Vibrio fischeri. This observation indicated that the absorption change determined by our method was a good indicator of heavy metal toxicity. The proposed method was more sensitive than conventional bioassays and could be used to detect metal toxicity at submicromolar concentrations of toxic metal ions.


Subject(s)
Metallothionein/chemistry , Metals, Heavy/toxicity , Spectrophotometry , Zinc/analysis , Biological Assay
7.
Article in English | MEDLINE | ID: mdl-20042364

ABSTRACT

A new simple method for the spectrophotometric determination of Pb(II) in fly ash leachates was developed. These leachates tend to contain a large amount of Ca(II) and Zn(II); this interferes with spectrophotometric determination of Pb(II) when conventional colorimetric agents are used. A copolymer consisting of protoporphyrin IX disodium salt and acrylamide was synthesized as a colorimetric agent. A measuring reagent containing ethylenediamine-N,N'-dipropionic acid (EDDP) as a masking agent for Zn(II) and an appropriate amount of Ca(II) together with the copolymer was applied to determine Pb(II). The temporal change in the absorption spectrum of the measuring reagent was acquired with a newly developed portable spectrophotometer for this method. The composition of EDDP and Ca(II) in the measuring reagent was optimized to measure leachates contaminated with Ca(II) and Zn(II). The detection limit and relative standard deviation of Pb(II) measured using the optimized method were 0.05 mg L(-1) and 2.3%, respectively. The tolerance limits for Ca(II) and Zn(II) contaminants, where errors of less than 10% were allowed at a concentration of 0.5 mg L(-1) Pb(II), were 4000 and 4 mg L(-1), respectively. The determination of Pb(II) in various samples of actual leachates from incinerator fly ash was examined with this method. The obtained values correlated well with those obtained by flame atomic absorption spectroscopy.


Subject(s)
Carbon/chemistry , Lead/analysis , Particulate Matter/chemistry , Spectrophotometry/methods , Coal Ash , Limit of Detection
8.
Article in English | MEDLINE | ID: mdl-19913455

ABSTRACT

For the purpose of detection of multimetal components in environment, alteration of the spectrophotometrical metal sensitivity of porphyrin was attempted. Two porphyrin-incorporated polymers were newly synthesized by the free radical copolymerization of protoporphyrin IX disodium salt and vinyl monomers, and their metal sensitivities were examined by measuring the difference absorption spectra. These porphyrin-incorporated polymers showed different metal sensitivities and their sensitivities were altered by change of pH. Three measuring reagents, which were different in the combination of the porphyrin-incorporated polymers and pH, were used for the simultaneous detection of multimetal components in metal ion mixtures. The difference spectra of these reagents showed the separate peaks corresponding to six metal ions, Bi(III), Co(II), Cu(II), Mn(II), Pb(II), and Zn(II). The spectra were acquired reproducibly by using standard normal variate (SNV) transformation. Furthermore, this method was applied to detect multimetal components in water samples such as tap water and industrial effluent.


Subject(s)
Metals/analysis , Polymers , Porphyrins/chemistry , Spectrophotometry/methods , Hydrogen-Ion Concentration , Molecular Structure , Polymers/chemical synthesis , Polymers/chemistry , Water/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...